Focused On-demand Library for Adrenocortical dysplasia protein homolog

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96AP0

UPID:

ACD_HUMAN

Alternative names:

POT1 and TIN2-interacting protein

Alternative UPACC:

Q96AP0; A0A0C4DGT6; Q562H5; Q9H8F9

Background:

The Adrenocortical dysplasia protein homolog, also known as POT1 and TIN2-interacting protein, plays a crucial role in telomere maintenance. As a component of the shelterin complex, it regulates telomere length and protection, ensuring chromosome ends are shielded from DNA damage surveillance. Its interaction with POT1 and modulation of telomere elongation are vital for cellular longevity and genomic stability.

Therapeutic significance:

Dyskeratosis congenita, both autosomal dominant and recessive forms, are linked to mutations in this protein, highlighting its critical role in telomere maintenance disorders. Understanding the Adrenocortical dysplasia protein homolog could pave the way for innovative treatments targeting bone marrow failure, pulmonary fibrosis, and other telomere-related conditions.